Corporate
2022.01.11
Lumosa Receives U.S. FDA Fast Track Designation for Its LT3001, a Novel Drug for the Treatment of Acute Ischemic Stroke
Corporate
2021.12.29
Lumosa Receives Market Approval for Its Long-Acting Analgesic Injection from Thailand
Corporate
2021.12.24
Phase 2 IND for Lumosa's Novel Stroke Therapy Approved by Taiwan FDA
A Multiple-dose of LT3001 to be Administered in Combination with Mechanical Thrombectomy
Corporate
2021.11.16
LT1001 Formulation Patent Granted by JPO
Corporate
2021.09.16
Lumosa Therapeutics Announces FDA Clearance of IND Application Its LT3001, a New Drug for the Treatment of Acute Ischemic Stroke, for Multi-dose Phase 2 Trial in Combination with Mechanical Thrombectomy
Corporate
2021.09.05
Lumosa CEO's Interview by Kevin Price on the Price of Business Show